Search

Your search keyword '"Grillo, Giovanni"' showing total 12 results
Start Over Author "Grillo, Giovanni" Database OAIster
12 results on '"Grillo, Giovanni"'

1. Anti-CD38 monoclonal antibody impairs CD34+ mobilization and affects clonogenic potential in multiple myeloma patients

Author

Zappaterra, A, Civettini, I, Cafro, A, Pezzetti, L, Pierini, S, Anghilieri, M, Bellio, L, Bertazzoni, P, Grillo, G, Minga, P, Pioltelli, M, Ravano, E, Sassone, M, Viganò, C, Volpato, E, Gambacorti-Passerini, C, Rossini, S, Cairoli, R, Crocchiolo, R, Zappaterra, Arianna, Civettini, Ivan, Cafro, Anna Maria, Pezzetti, Laura, Pierini, Silvia, Anghilieri, Michela, Bellio, Laura, Bertazzoni, Paola, Grillo, Giovanni, Minga, Periana, Pioltelli, Maria L, Ravano, Emanuele, Sassone, Marianna, Viganò, Clara V, Volpato, Elisabetta B, Gambacorti-Passerini, Carlo, Rossini, Silvano, Cairoli, Roberto, Crocchiolo, Roberto, Zappaterra, A, Civettini, I, Cafro, A, Pezzetti, L, Pierini, S, Anghilieri, M, Bellio, L, Bertazzoni, P, Grillo, G, Minga, P, Pioltelli, M, Ravano, E, Sassone, M, Viganò, C, Volpato, E, Gambacorti-Passerini, C, Rossini, S, Cairoli, R, Crocchiolo, R, Zappaterra, Arianna, Civettini, Ivan, Cafro, Anna Maria, Pezzetti, Laura, Pierini, Silvia, Anghilieri, Michela, Bellio, Laura, Bertazzoni, Paola, Grillo, Giovanni, Minga, Periana, Pioltelli, Maria L, Ravano, Emanuele, Sassone, Marianna, Viganò, Clara V, Volpato, Elisabetta B, Gambacorti-Passerini, Carlo, Rossini, Silvano, Cairoli, Roberto, and Crocchiolo, Roberto

Published
2024

2. Multiparametric Flow Cytometry-MRD Assay: Lesson from Phase II Trail REL AML 001

Author

Gatti, A, Veronese, S, Grillo, G, Di Camillo, B, Fumagalli, M, Krampera, M, Zappasodi, P, Borlenghi, E, Todisco, E, Ubezio, M, Bernardi, M, Molteni, A, Basilico, C, Turrini, M, Greco, R, Mancini, V, Riva, M, Magliano, G, Stefanucci, M, Brando, B, Beghini, A, Cairoli, R, Gatti, Arianna, Veronese, Silvio, Grillo, Giovanni, Di Camillo, Barbara, Fumagalli, Monica, Krampera, Mauro, Zappasodi, Patrizia, Borlenghi, Erika, Todisco, Elisabetta, Ubezio, Marta, Bernardi, Massimo, Molteni, Alfredo, Basilico, Claudia, Turrini, Mauro, Greco, Rosa, Mancini, Valentina, Riva, Marta, Magliano, Gabriele, Stefanucci, Marta Rachele, Brando, Bruno, Beghini, Alessandro, Cairoli, Roberto, Gatti, A, Veronese, S, Grillo, G, Di Camillo, B, Fumagalli, M, Krampera, M, Zappasodi, P, Borlenghi, E, Todisco, E, Ubezio, M, Bernardi, M, Molteni, A, Basilico, C, Turrini, M, Greco, R, Mancini, V, Riva, M, Magliano, G, Stefanucci, M, Brando, B, Beghini, A, Cairoli, R, Gatti, Arianna, Veronese, Silvio, Grillo, Giovanni, Di Camillo, Barbara, Fumagalli, Monica, Krampera, Mauro, Zappasodi, Patrizia, Borlenghi, Erika, Todisco, Elisabetta, Ubezio, Marta, Bernardi, Massimo, Molteni, Alfredo, Basilico, Claudia, Turrini, Mauro, Greco, Rosa, Mancini, Valentina, Riva, Marta, Magliano, Gabriele, Stefanucci, Marta Rachele, Brando, Bruno, Beghini, Alessandro, and Cairoli, Roberto

Published
2023

3. Evaluating the performance of large language models in haematopoietic stem cell transplantation decision-making

Author

Civettini, I, Zappaterra, A, Granelli, B, Rindone, G, Aroldi, A, Bonfanti, S, Colombo, F, Fedele, M, Grillo, G, Parma, M, Perfetti, P, Terruzzi, E, Gambacorti-Passerini, C, Ramazzotti, D, Cavalca, F, Civettini, Ivan, Zappaterra, Arianna, Granelli, Bianca Maria, Rindone, Giovanni, Aroldi, Andrea, Bonfanti, Stefano, Colombo, Federica, Fedele, Marilena, Grillo, Giovanni, Parma, Matteo, Perfetti, Paola, Terruzzi, Elisabetta, Gambacorti-Passerini, Carlo, Ramazzotti, Daniele, Cavalca, Fabrizio, Civettini, I, Zappaterra, A, Granelli, B, Rindone, G, Aroldi, A, Bonfanti, S, Colombo, F, Fedele, M, Grillo, G, Parma, M, Perfetti, P, Terruzzi, E, Gambacorti-Passerini, C, Ramazzotti, D, Cavalca, F, Civettini, Ivan, Zappaterra, Arianna, Granelli, Bianca Maria, Rindone, Giovanni, Aroldi, Andrea, Bonfanti, Stefano, Colombo, Federica, Fedele, Marilena, Grillo, Giovanni, Parma, Matteo, Perfetti, Paola, Terruzzi, Elisabetta, Gambacorti-Passerini, Carlo, Ramazzotti, Daniele, and Cavalca, Fabrizio

Abstract

In a first-of-its-kind study, we assessed the capabilities of large language models (LLMs) in making complex decisions in haematopoietic stem cell transplantation. The evaluation was conducted not only for Generative Pre-trained Transformer 4 (GPT-4) but also conducted on other artificial intelligence models: PaLm 2 and Llama-2. Using detailed haematological histories that include both clinical, molecular and donor data, we conducted a triple-blind survey to compare LLMs to haematology residents. We found that residents significantly outperformed LLMs (p = 0.02), particularly in transplant eligibility assessment (p = 0.01). Our triple-blind methodology aimed to mitigate potential biases in evaluating LLMs and revealed both their promise and limitations in deciphering complex haematological clinical scenarios.

Published
2023

4. Hematopoietic stem cell transplantation for adults with relapsed acute promyelocytic leukemia in second complete remission

Author

Sanz, Jaime, Labopin, Myriam, Sanz, Miguel A., Aljurf, Mahmoud, Sousa, Aida Botelho, Craddock, Charles, Zuckerman, Tsila, Labussière-Wallet, Hélène, Campos, Antonio, Grillo, Giovanni, Ozkurt, Zubeyde Nur, Cornelissen, J. J., Reményi, Péter, Martino, Massimo, Porras, Rocio Parody, Nagler, Arnon, Gorin, Norbert Claude, Mohty, Mohamad, Sanz, Jaime, Labopin, Myriam, Sanz, Miguel A., Aljurf, Mahmoud, Sousa, Aida Botelho, Craddock, Charles, Zuckerman, Tsila, Labussière-Wallet, Hélène, Campos, Antonio, Grillo, Giovanni, Ozkurt, Zubeyde Nur, Cornelissen, J. J., Reményi, Péter, Martino, Massimo, Porras, Rocio Parody, Nagler, Arnon, Gorin, Norbert Claude, and Mohty, Mohamad

Abstract

We retrospectively compared outcomes of a large series of adult patients with APL in CR2 receiving alloHSCT (n = 228) or autoHSCT (n = 341) reported to the European Society for Blood and Marrow Transplantation from January 2004 to December 2018. The 2-year cumulative incidence of non-relapse mortality was significantly higher for alloHSCT 17.3% (95% CI 12.5–22.8) compared with autoHSCT 2.7% (95% CI 1.2–5) (p = 0.001), while differences in relapse rate were not significant (28% versus 22.9%; p = 0.28). Leukemia-free survival (LFS) and overall survival (OS) favored autoHSCT with 74.5% (95% CI 69–79.2) and 82.4% (95% CI 77.3–86.5) compared with alloHSCT with 54.7% (95% CI 47.5–61.3) (p = 0.001) and 64.3% (95% CI 57.2–70.6), respectively (p = 0.001 and p = 0.001). Multivariable analysis showed significantly worse LFS after alloHSCT (HR 0.49; 95% CI 0.37–0.67; p < 0.0001), older age (p = 0.001), and shorter time from diagnosis to transplant (p = 0.00015). Similar results were obtained for OS. The study shows that autoHSCT resulted in better survival outcomes (LFS and OS) for APL in CR2. These results were mainly due to reduced NRM in the autoHSCT as compared to alloHSCT.

Published
2021

5. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors. A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (Gitmo)

Author

Candoni, Anna, Rambaldi, Alessandro, Fanin, Renato, Velardi, Andrea, Arcese, William, Ciceri, Fabio, Lazzarotto, Davide, Lussana, Federico, Olivieri, Jacopo, Grillo, Giovanni, Parma, Matteo, Bruno, Benedetto, Sora', Federica, Bernasconi, Paolo, Saccardi, Riccardo, Foa, Robin, Sessa, Mariarosa, Bresciani, Paola, Giglio, Fabio, Picardi, Alessandra, Busca, Alessandro, Sica, Simona, Perruccio, Katia, Zucchetti, Elisa, Diral, Elisa, Iori, Anna Paola, Colombo, Anna Amelia, Tringali, Stefano, Santarone, Stella, Irrera, Giuseppe, Mancini, Stefano, Zallio, Francesco, Malagola, Michele, Albano, Francesco, Carella, Angelo Michele, Olivieri, Attilio, Tecchio, Cristina, Dominietto, Alida, Vacca, Adriana, Sorasio, Roberto, Orciuolo, Enrico, Risitano, Antonio Maria, Leotta, Salvatore Nuccio, Cortelezzi, Agostino, Mammoliti, Sonia, Oldani, Elena, Bonifazi, Francesca, Sora, Federica (ORCID:0000-0002-9607-5298), Foà, Robin, Sica, Simona (ORCID:0000-0003-2426-3465), Candoni, Anna, Rambaldi, Alessandro, Fanin, Renato, Velardi, Andrea, Arcese, William, Ciceri, Fabio, Lazzarotto, Davide, Lussana, Federico, Olivieri, Jacopo, Grillo, Giovanni, Parma, Matteo, Bruno, Benedetto, Sora', Federica, Bernasconi, Paolo, Saccardi, Riccardo, Foa, Robin, Sessa, Mariarosa, Bresciani, Paola, Giglio, Fabio, Picardi, Alessandra, Busca, Alessandro, Sica, Simona, Perruccio, Katia, Zucchetti, Elisa, Diral, Elisa, Iori, Anna Paola, Colombo, Anna Amelia, Tringali, Stefano, Santarone, Stella, Irrera, Giuseppe, Mancini, Stefano, Zallio, Francesco, Malagola, Michele, Albano, Francesco, Carella, Angelo Michele, Olivieri, Attilio, Tecchio, Cristina, Dominietto, Alida, Vacca, Adriana, Sorasio, Roberto, Orciuolo, Enrico, Risitano, Antonio Maria, Leotta, Salvatore Nuccio, Cortelezzi, Agostino, Mammoliti, Sonia, Oldani, Elena, Bonifazi, Francesca, Sora, Federica (ORCID:0000-0002-9607-5298), Foà, Robin, and Sica, Simona (ORCID:0000-0003-2426-3465)

Abstract

PURPOSE: We performed a nationwide registry-based analysis to describe the clinical outcome of adults patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who underwent an allogeneic hematopoietic stem cell transplantation (HSCT) after a TKI-based treatment. PATIENTS AND RESULTS: A total of 441 patients were included in the study. The median age at HSCT was 44 years (range 18-70). All the 441 patients (100%) received TKI before the HSCT (performed between 2005 and 2016). Of these patients, 404 (92%) were in cytologic complete remission (CR), while the remaining 37 (8%) had an active disease at the time of HSCT. Molecular minimal residual disease (MRD) was negative in 147 patients (36%) at the time of HSCT. The donor was unrelated in 46% of cases. The prevalent source of stem cells was peripheral blood (70%). The conditioning regimen was myeloablative in 82% of cases (TBI-based in 50%) and included ATG in 51% of cases. With a median follow-up after HSCT of 39.4 months (range: 1-145), the overall survival (OS) probability at 1, 2 and 5 years was 69.6%, 61.1% and 50.3%, respectively, with a median OS of 62 months. Progression-free survival (PFS) at 1, 2 and 5 years was 60.2%, 52.1% and 43.7%, respectively. OS and PFS were significantly better in patients with CR and MRD-negative at the time of transplant compared with those of patients with CR but MRD-positive (50% OS not reached vs. 36 months, P=0.015; 50% PFS not reached vs. 26 months, P=0.003). The subgroup of MRD-negative patients both at HSCT and at 3 months after HSCT had a better outcome (5 years OS rate 70%). Conversely, the 37 patients who underwent a HSCT with active Ph+ ALL had a median OS and PFS of 7 and 5 months, respectively. The 5 years cumulative incidence of relapse was significantly lower in MRD-negative patients (19.5% vs. 35.4%, P=0.001). The non-relapse mortality (NRM) after 1, 2 and 5 years was 19.1% (95%CI: 15.5-22.9), 20.7% (95%CI: 17-24.7) and 24.1% (9

Published
2019

8. ABIVRATIO || MVLTORVM ER-||RORVM HAERE-||TICORVM,|| PVBLICE ET SPON-||TE EDITA A D. IOANNE MAT-||thaeo Grillo Ciue Sa-||lernitano,|| Coram ... Cardinale Ar-||miniacco, et ... Ar-||chiepiscopo Auenionense ... || Adiecta est eiusdem epistola, qua causae re-||uersionis ad fidem catholicam || exponuntur.

Author

Grillo, Giovanni Matteo and Grillo, Giovanni Matteo

Abstract

Vorlageform des Erscheinungsvermerks: M.D.LXV[III.]||(DILINGAE || Impressum ex certa scientia et vo-||luntate Reuerendiss. Domi-||ni Ordinarij.||) [Sebald Mayer]

9. ABIVRATIO || MVLTORVM ER-||RORVM HAERE-||TICORVM,|| PVBLICE ET SPON-||TE EDITA A D. IOANNE MAT-||thaeo Grillo Ciue Sa-||lernitano,|| Coram ... Cardinale Ar-||miniacco, et ... Ar-||chiepiscopo Auenionense ... || Adiecta est eiusdem epistola, qua causae re-||uersionis ad fidem catholicam || exponuntur.

Author

Grillo, Giovanni Matteo and Grillo, Giovanni Matteo

Abstract

Vorlageform des Erscheinungsvermerks: M.D.LXV[III.]||(DILINGAE || Impressum ex certa scientia et vo-||luntate Reuerendiss. Domi-||ni Ordinarij.||) [Sebald Mayer]

12. ABIVRATIO || MVLTORVM ER-||RORVM HAERE-||TICORVM,|| PVBLICE ET SPON-||TE EDITA A D. IOANNE MAT-||thaeo Grillo Ciue Sa-||lernitano,|| Coram ... Cardinale Ar-||miniacco, et ... Ar-||chiepiscopo Auenionense ... || Adiecta est eiusdem epistola, qua causae re-||uersionis ad fidem catholicam || exponuntur.

Author

Grillo, Giovanni Matteo and Grillo, Giovanni Matteo

Abstract

Vorlageform des Erscheinungsvermerks: M.D.LXV[III.]||(DILINGAE || Impressum ex certa scientia et vo-||luntate Reuerendiss. Domi-||ni Ordinarij.||) [Sebald Mayer]

Catalog

Books, media, physical & digital resources
See catalog results